Lv2
120 积分 2026-06-01 加入
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
1天前
待确认
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2个月前
已完结
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
3个月前
已完结
Interstitial lung diseases
3个月前
已完结
Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment
3个月前
已完结
Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas
3个月前
已完结
皖公网安备34019202002308
